Fed. Circ. Panel Walks Back $235M Skinny Label Ruling
A Federal Circuit panel on Tuesday vacated its October finding that Teva induced infringement of a patent covering GlaxoSmithKline's drug Coreg to the tune of $235 million and set a new...To view the full article, register now.
Already a subscriber? Click here to view full article